Nonalcoholic Steatohepatitis (Nash) Market Report

Japan Nonalcoholic Steatohepatitis (Nash) Market Professional Research Report 2014-2026, Segmented by Players, Types, End-Users in Major Region

  • POSTDATE：Sep 14, 2019
  • PAGES：203
  • REPORT CODE：GMM218118
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • This report offers an overview of the market trends, drivers, and barriers with respect to the Japan Nonalcoholic Steatohepatitis (Nash) market. It also provides a detailed overview of the market of different regions across Hokkaido, Tohoku, Kanto, Chubu, Kinki, Chugoku, Shikoku, Kyushu. The report deep analyzes type and application in Japan Nonalcoholic Steatohepatitis (Nash) market. Detailed analysis of key players, along with key growth strategies adopted by Nonalcoholic Steatohepatitis (Nash) industry, the PEST and SWOT analysis are also included. In short, the report will provide a comprehensive view of the industry's development and features.


    By Player:

    • Astazeneca Plc

    • Enzo Biochem, Inc

    • Novo Nordisk

    • Gilead Science

    • Boehringer Ingelheim

    • Nimbus Therapeutics

    • Verva Pharmaceuticals

    • Galmed Pharmaceuticals Ltd.

    • Islet Sciences

    • AstraZeneca

    • GENFIT SA

    • Connexios Life Sciences

    • Tobira Therapeutics, Inc.

    • Cerenis Therapeutics

    • Viking Therapeutics

    • Immuron Ltd

    • Intercepts Pharmaceuticals


    By Type:

    • Weight Loss Treatment

    • Insulin-Sensitizing Agents

    • Lipid-Lowering Drugs

    • Antioxidants

    • Other Agents


    By End-User:

    • Phase I

    • Phase II

    • Phase III

    • Clinical Trials


    By Region:

    • Hokkaido

    • Tohoku

    • Kanto

    • Chubu

    • Kinki

    • Chugoku

    • Shikoku

    • Kyushu

  • 1 Report Overview

    • 1.1 Product Definition and Scope

    • 1.2 PEST (Political, Economic, Social and Technological) Analysis of Nonalcoholic Steatohepatitis (Nash) Market

    • 1.3 Market Segment by Type

      • 1.3.1 Japan Nonalcoholic Steatohepatitis (Nash) Market Size and Growth Rate of Weight Loss Treatment from 2014 to 2026

      • 1.3.2 Japan Nonalcoholic Steatohepatitis (Nash) Market Size and Growth Rate of Insulin-Sensitizing Agents from 2014 to 2026

      • 1.3.3 Japan Nonalcoholic Steatohepatitis (Nash) Market Size and Growth Rate of Lipid-Lowering Drugs from 2014 to 2026

      • 1.3.4 Japan Nonalcoholic Steatohepatitis (Nash) Market Size and Growth Rate of Antioxidants from 2014 to 2026

      • 1.3.5 Japan Nonalcoholic Steatohepatitis (Nash) Market Size and Growth Rate of Other Agents from 2014 to 2026

    • 1.4 Market Segment by Application

      • 1.4.1 Japan Nonalcoholic Steatohepatitis (Nash) Market Size and Growth Rate of Phase I from 2014 to 2026

      • 1.4.2 Japan Nonalcoholic Steatohepatitis (Nash) Market Size and Growth Rate of Phase II from 2014 to 2026

      • 1.4.3 Japan Nonalcoholic Steatohepatitis (Nash) Market Size and Growth Rate of Phase III from 2014 to 2026

      • 1.4.4 Japan Nonalcoholic Steatohepatitis (Nash) Market Size and Growth Rate of Clinical Trials from 2014 to 2026

    • 1.5 Market Segment by Regions

      • 1.5.1 Hokkaido Nonalcoholic Steatohepatitis (Nash) Consumption Market Size and Growth Rate from 2014 to 2026

      • 1.5.2 Tohoku Nonalcoholic Steatohepatitis (Nash) Consumption Market Size and Growth Rate from 2014 to 2026

      • 1.5.3 Kanto Nonalcoholic Steatohepatitis (Nash) Consumption Market Size and Growth Rate from 2014 to 2026

      • 1.5.4 Chubu Nonalcoholic Steatohepatitis (Nash) Consumption Market Size and Growth Rate from 2014 to 2026

      • 1.5.5 Kinki Nonalcoholic Steatohepatitis (Nash) Consumption Market Size and Growth Rate from 2014 to 2026

      • 1.5.6 Chugoku Nonalcoholic Steatohepatitis (Nash) Consumption Market Size and Growth Rate from 2014 to 2026

      • 1.5.7 Shikoku Nonalcoholic Steatohepatitis (Nash) Consumption Market Size and Growth Rate from 2014 to 2026

      • 1.5.8 Kyushu Nonalcoholic Steatohepatitis (Nash) Consumption Market Size and Growth Rate from 2014 to 2026


    2 Market Trends and Competitive Landscape

    • 2.1 Market Trends and Dynamics

      • 2.1.1 Market Challenges and Restraints

      • 2.1.2 Market Opportunities and Potentials

      • 2.1.3 Mergers and Acquisitions

    • 2.2 Competitive Landscape Analysis

      • 2.2.1 Industrial Concentration Analysis

      • 2.2.2 Porter's Five Forces Analysis of the Industry

      • 2.2.3 SWOT Analysis for New Entrants


    3 Segmentation of Nonalcoholic Steatohepatitis (Nash) Market by Types

    • 3.1 Products Development Trends of Different Types

    • 3.2 Commercial Products Types of Major Vendors

    • 3.3 Competitive Landscape Analysis of Different Types

    • 3.4 Market Size of Nonalcoholic Steatohepatitis (Nash) by Major Types

      • 3.4.1 Market Size and Growth Rate of Weight Loss Treatment

      • 3.4.2 Market Size and Growth Rate of Insulin-Sensitizing Agents

      • 3.4.3 Market Size and Growth Rate of Lipid-Lowering Drugs

      • 3.4.4 Market Size and Growth Rate of Antioxidants

      • 3.4.5 Market Size and Growth Rate of Other Agents

    4 Segmentation of Nonalcoholic Steatohepatitis (Nash) Market by End-Users

    • 4.1 Downstream Client Analysis by End-Users

    • 4.2 Competitive Landscape Analysis of Different End-Users

    • 4.3 Market Potential Analysis of Different End-Users

    • 4.4 Market Size of Nonalcoholic Steatohepatitis (Nash) by Major End-Users

      • 4.4.1 Market Size and Growth Rate of Nonalcoholic Steatohepatitis (Nash) in Phase I

      • 4.4.2 Market Size and Growth Rate of Nonalcoholic Steatohepatitis (Nash) in Phase II

      • 4.4.3 Market Size and Growth Rate of Nonalcoholic Steatohepatitis (Nash) in Phase III

      • 4.4.4 Market Size and Growth Rate of Nonalcoholic Steatohepatitis (Nash) in Clinical Trials


    5 Market Analysis by Regions

    • 5.1 Japan Nonalcoholic Steatohepatitis (Nash) Production Analysis by Regions

    • 5.2 Japan Nonalcoholic Steatohepatitis (Nash) Consumption Analysis by Regions


    6 Hokkaido Nonalcoholic Steatohepatitis (Nash) Landscape Analysis

    • 6.1 Hokkaido Nonalcoholic Steatohepatitis (Nash) Landscape Analysis by Major Types

    • 6.2 Hokkaido Nonalcoholic Steatohepatitis (Nash) Landscape Analysis by Major End-Users


    7 Tohoku Nonalcoholic Steatohepatitis (Nash) Landscape Analysis

    • 7.1 Tohoku Nonalcoholic Steatohepatitis (Nash) Landscape Analysis by Major Types

    • 7.2 Tohoku Nonalcoholic Steatohepatitis (Nash) Landscape Analysis by Major End-Users


    8 Kanto Nonalcoholic Steatohepatitis (Nash) Landscape Analysis

    • 8.1 Kanto Nonalcoholic Steatohepatitis (Nash) Landscape Analysis by Major Types

    • 8.2 Kanto Nonalcoholic Steatohepatitis (Nash) Landscape Analysis by Major End-Users


    9 Chubu Nonalcoholic Steatohepatitis (Nash) Landscape Analysis

    • 9.1 Chubu Nonalcoholic Steatohepatitis (Nash) Landscape Analysis by Major Types

    • 9.2 Chubu Nonalcoholic Steatohepatitis (Nash) Landscape Analysis by Major End-Users


    10 Kinki Nonalcoholic Steatohepatitis (Nash) Landscape Analysis

    • 10.1 Kinki Nonalcoholic Steatohepatitis (Nash) Landscape Analysis by Major Types

    • 10.2 Kinki Nonalcoholic Steatohepatitis (Nash) Landscape Analysis by Major End-Users


    11 Chugoku Nonalcoholic Steatohepatitis (Nash) Landscape Analysis

    • 11.1 Chugoku Nonalcoholic Steatohepatitis (Nash) Landscape Analysis by Major Types

    • 11.2 Chugoku Nonalcoholic Steatohepatitis (Nash) Landscape Analysis by Major End-Users


    12 Shikoku Nonalcoholic Steatohepatitis (Nash) Landscape Analysis

    • 12.1 Shikoku Nonalcoholic Steatohepatitis (Nash) Landscape Analysis by Major Types

    • 12.2 Shikoku Nonalcoholic Steatohepatitis (Nash) Landscape Analysis by Major End-Users


    13 Kyushu Nonalcoholic Steatohepatitis (Nash) Landscape Analysis

    • 13.1 Kyushu Nonalcoholic Steatohepatitis (Nash) Landscape Analysis by Major Types

    • 13.2 Kyushu Nonalcoholic Steatohepatitis (Nash) Landscape Analysis by Major End-Users


    14 Major Players Profiles

    • 14.1 Astazeneca Plc

      • 14.1.1 Astazeneca Plc Company Profile and Recent Development

      • 14.1.2 Market Performance

      • 14.1.3 Product and Service Introduction

    • 14.2 Enzo Biochem, Inc

      • 14.2.1 Enzo Biochem, Inc Company Profile and Recent Development

      • 14.2.2 Market Performance

      • 14.2.3 Product and Service Introduction

    • 14.3 Novo Nordisk

      • 14.3.1 Novo Nordisk Company Profile and Recent Development

      • 14.3.2 Market Performance

      • 14.3.3 Product and Service Introduction

    • 14.4 Gilead Science

      • 14.4.1 Gilead Science Company Profile and Recent Development

      • 14.4.2 Market Performance

      • 14.4.3 Product and Service Introduction

    • 14.5 Boehringer Ingelheim

      • 14.5.1 Boehringer Ingelheim Company Profile and Recent Development

      • 14.5.2 Market Performance

      • 14.5.3 Product and Service Introduction

    • 14.6 Nimbus Therapeutics

      • 14.6.1 Nimbus Therapeutics Company Profile and Recent Development

      • 14.6.2 Market Performance

      • 14.6.3 Product and Service Introduction

    • 14.7 Verva Pharmaceuticals

      • 14.7.1 Verva Pharmaceuticals Company Profile and Recent Development

      • 14.7.2 Market Performance

      • 14.7.3 Product and Service Introduction

    • 14.8 Galmed Pharmaceuticals Ltd.

      • 14.8.1 Galmed Pharmaceuticals Ltd. Company Profile and Recent Development

      • 14.8.2 Market Performance

      • 14.8.3 Product and Service Introduction

    • 14.9 Islet Sciences

      • 14.9.1 Islet Sciences Company Profile and Recent Development

      • 14.9.2 Market Performance

      • 14.9.3 Product and Service Introduction

    • 14.10 AstraZeneca

      • 14.10.1 AstraZeneca Company Profile and Recent Development

      • 14.10.2 Market Performance

      • 14.10.3 Product and Service Introduction

    • 14.11 GENFIT SA

      • 14.11.1 GENFIT SA Company Profile and Recent Development

      • 14.11.2 Market Performance

      • 14.11.3 Product and Service Introduction

    • 14.12 Connexios Life Sciences

      • 14.12.1 Connexios Life Sciences Company Profile and Recent Development

      • 14.12.2 Market Performance

      • 14.12.3 Product and Service Introduction

    • 14.13 Tobira Therapeutics, Inc.

      • 14.13.1 Tobira Therapeutics, Inc. Company Profile and Recent Development

      • 14.13.2 Market Performance

      • 14.13.3 Product and Service Introduction

    • 14.14 Cerenis Therapeutics

      • 14.14.1 Cerenis Therapeutics Company Profile and Recent Development

      • 14.14.2 Market Performance

      • 14.14.3 Product and Service Introduction

    • 14.15 Viking Therapeutics

      • 14.15.1 Viking Therapeutics Company Profile and Recent Development

      • 14.15.2 Market Performance

      • 14.15.3 Product and Service Introduction

    • 14.16 Immuron Ltd

      • 14.16.1 Immuron Ltd Company Profile and Recent Development

      • 14.16.2 Market Performance

      • 14.16.3 Product and Service Introduction

    • 14.17 Intercepts Pharmaceuticals

      • 14.17.1 Intercepts Pharmaceuticals Company Profile and Recent Development

      • 14.17.2 Market Performance

      • 14.17.3 Product and Service Introduction

     

    The List of Tables and Figures (Totals 125 Figures and 158 Tables)

     

    • Figure Japan Nonalcoholic Steatohepatitis (Nash) Market Size and Growth Rate of Weight Loss Treatment from 2014 to 2026

    • Figure Japan Nonalcoholic Steatohepatitis (Nash) Market Size and Growth Rate of Insulin-Sensitizing Agents from 2014 to 2026

    • Figure Japan Nonalcoholic Steatohepatitis (Nash) Market Size and Growth Rate of Lipid-Lowering Drugs from 2014 to 2026

    • Figure Japan Nonalcoholic Steatohepatitis (Nash) Market Size and Growth Rate of Antioxidants from 2014 to 2026

    • Figure Japan Nonalcoholic Steatohepatitis (Nash) Market Size and Growth Rate of Other Agents from 2014 to 2026

    • Figure Market Share by Type in 2014

    • Figure Market Share by Type in 2018

    • Figure Market Share by Type in 2026

    • Figure Japan Nonalcoholic Steatohepatitis (Nash) Market Size and Growth Rate of Phase I from 2014 to 2026

    • Figure Japan Nonalcoholic Steatohepatitis (Nash) Market Size and Growth Rate of Phase II from 2014 to 2026

    • Figure Japan Nonalcoholic Steatohepatitis (Nash) Market Size and Growth Rate of Phase III from 2014 to 2026

    • Figure Japan Nonalcoholic Steatohepatitis (Nash) Market Size and Growth Rate of Clinical Trials from 2014 to 2026

    • Figure Market Share by End-User in 2014

    • Figure Market Share by End-User in 2018

    • Figure Market Share by End-User in 2026

    • Figure Hokkaido Nonalcoholic Steatohepatitis (Nash) Consumption Market Size and Growth Rate from 2014 to 2026

    • Figure Tohoku Nonalcoholic Steatohepatitis (Nash) Consumption Market Size and Growth Rate from 2014 to 2026

    • Figure Kanto Nonalcoholic Steatohepatitis (Nash) Consumption Market Size and Growth Rate from 2014 to 2026

    • Figure Chubu Nonalcoholic Steatohepatitis (Nash) Consumption Market Size and Growth Rate from 2014 to 2026

    • Figure Kinki Nonalcoholic Steatohepatitis (Nash) Consumption Market Size and Growth Rate from 2014 to 2026

    • Figure Chugoku Nonalcoholic Steatohepatitis (Nash) Consumption Market Size and Growth Rate from 2014 to 2026

    • Figure Shikoku Nonalcoholic Steatohepatitis (Nash) Consumption Market Size and Growth Rate from 2014 to 2026

    • Figure Kyushu Nonalcoholic Steatohepatitis (Nash) Consumption Market Size and Growth Rate from 2014 to 2026

    • Figure Development Trends and Industry Dynamics of Nonalcoholic Steatohepatitis (Nash) Industry

    • Figure Market Challenges and Restraints

    • Figure Market Opportunities and Potentials

    • Table Mergers and Acquisition

    • Figure Market Share of TOP 3 Players in 2018

    • Figure Market Share of TOP 5 Players in 2018

    • Figure Market Share of TOP 6 Players from 2014 to 2019

    • Figure Porter's Five Forces Analysis

    • Figure New Entrant SWOT Analysis

    • Table Specifications of Different Types of Nonalcoholic Steatohepatitis (Nash)

    • Figure Development Trends of Different Types

    • Table Commercial Products Types of Major Vendors

    • Figure Competitive Landscape Analysis of Different Types

    • Table Consumption of Nonalcoholic Steatohepatitis (Nash) by Different Types from 2014 to 2026

    • Table Consumption Share of Nonalcoholic Steatohepatitis (Nash) by Different Types from 2014 to 2026

    • Figure Market Size and Growth Rate of Weight Loss Treatment

    • Figure Market Size and Growth Rate of Insulin-Sensitizing Agents

    • Figure Market Size and Growth Rate of Lipid-Lowering Drugs

    • Figure Market Size and Growth Rate of Antioxidants

    • Figure Market Size and Growth Rate of Other Agents

    • Table Downstream Client Analysis by End-Users

    • Figure Competitive Landscape Analysis of Different End-Users

    • Table Market Potential Analysis of Different End-Users

    • Table Consumption of Nonalcoholic Steatohepatitis (Nash) by Different End-Users from 2014 to 2026

    • Table Consumption Share of Nonalcoholic Steatohepatitis (Nash) by Different End-Users from 2014 to 2026

    • Figure Japan Nonalcoholic Steatohepatitis (Nash) Market Size and Growth Rate of Phase I from 2014 to 2026

    • Figure Japan Nonalcoholic Steatohepatitis (Nash) Market Size and Growth Rate of Phase II from 2014 to 2026

    • Figure Japan Nonalcoholic Steatohepatitis (Nash) Market Size and Growth Rate of Phase III from 2014 to 2026

    • Figure Japan Nonalcoholic Steatohepatitis (Nash) Market Size and Growth Rate of Clinical Trials from 2014 to 2026

    • Table Japan Nonalcoholic Steatohepatitis (Nash) Production by Regions

    • Table Japan Nonalcoholic Steatohepatitis (Nash) Production Share by Regions

    • Figure Japan Nonalcoholic Steatohepatitis (Nash) Production Share by Regions in 2014

    • Figure Japan Nonalcoholic Steatohepatitis (Nash) Production Share by Regions in 2018

    • Figure Japan Nonalcoholic Steatohepatitis (Nash) Production Share by Regions in 2026

    • Table Japan Nonalcoholic Steatohepatitis (Nash) Consumption by Regions

    • Table Japan Nonalcoholic Steatohepatitis (Nash) Consumption Share by Regions

    • Figure Japan Nonalcoholic Steatohepatitis (Nash) Consumption Share by Regions in 2014

    • Figure Japan Nonalcoholic Steatohepatitis (Nash) Consumption Share by Regions in 2018

    • Figure Japan Nonalcoholic Steatohepatitis (Nash) Consumption Share by Regions in 2026

    • Table Hokkaido Nonalcoholic Steatohepatitis (Nash) Consumption by Types from 2014 to 2026

    • Table Hokkaido Nonalcoholic Steatohepatitis (Nash) Consumption Share by Types from 2014 to 2026

    • Figure Hokkaido Nonalcoholic Steatohepatitis (Nash) Consumption Share by Types in 2014

    • Figure Hokkaido Nonalcoholic Steatohepatitis (Nash) Consumption Share by Types in 2018

    • Figure Hokkaido Nonalcoholic Steatohepatitis (Nash) Consumption Share by Types in 2026

    • Table Hokkaido Nonalcoholic Steatohepatitis (Nash) Consumption by End-Users from 2014 to 2026

    • Table Hokkaido Nonalcoholic Steatohepatitis (Nash) Consumption Share by End-Users from 2014 to 2026

    • Figure Hokkaido Nonalcoholic Steatohepatitis (Nash) Consumption Share by End-Users in 2014

    • Figure Hokkaido Nonalcoholic Steatohepatitis (Nash) Consumption Share by End-Users in 2018

    • Figure Hokkaido Nonalcoholic Steatohepatitis (Nash) Consumption Share by End-Users in 2026

    • Table Tohoku Nonalcoholic Steatohepatitis (Nash) Consumption by Types from 2014 to 2026

    • Table Tohoku Nonalcoholic Steatohepatitis (Nash) Consumption Share by Types from 2014 to 2026

    • Figure Tohoku Nonalcoholic Steatohepatitis (Nash) Consumption Share by Types in 2014

    • Figure Tohoku Nonalcoholic Steatohepatitis (Nash) Consumption Share by Types in 2018

    • Figure Tohoku Nonalcoholic Steatohepatitis (Nash) Consumption Share by Types in 2026

    • Table Tohoku Nonalcoholic Steatohepatitis (Nash) Consumption by End-Users from 2014 to 2026

    • Table Tohoku Nonalcoholic Steatohepatitis (Nash) Consumption Share by End-Users from 2014 to 2026

    • Figure Tohoku Nonalcoholic Steatohepatitis (Nash) Consumption Share by End-Users in 2014

    • Figure Tohoku Nonalcoholic Steatohepatitis (Nash) Consumption Share by End-Users in 2018

    • Figure Tohoku Nonalcoholic Steatohepatitis (Nash) Consumption Share by End-Users in 2026

    • Table Kanto Nonalcoholic Steatohepatitis (Nash) Consumption by Types from 2014 to 2026

    • Table Kanto Nonalcoholic Steatohepatitis (Nash) Consumption Share by Types from 2014 to 2026

    • Figure Kanto Nonalcoholic Steatohepatitis (Nash) Consumption Share by Types in 2014

    • Figure Kanto Nonalcoholic Steatohepatitis (Nash) Consumption Share by Types in 2018

    • Figure Kanto Nonalcoholic Steatohepatitis (Nash) Consumption Share by Types in 2026

    • Table Kanto Nonalcoholic Steatohepatitis (Nash) Consumption by End-Users from 2014 to 2026

    • Table Kanto Nonalcoholic Steatohepatitis (Nash) Consumption Share by End-Users from 2014 to 2026

    • Figure Kanto Nonalcoholic Steatohepatitis (Nash) Consumption Share by End-Users in 2014

    • Figure Kanto Nonalcoholic Steatohepatitis (Nash) Consumption Share by End-Users in 2018

    • Figure Kanto Nonalcoholic Steatohepatitis (Nash) Consumption Share by End-Users in 2026

    • Table Chubu Nonalcoholic Steatohepatitis (Nash) Consumption by Types from 2014 to 2026

    • Table Chubu Nonalcoholic Steatohepatitis (Nash) Consumption Share by Types from 2014 to 2026

    • Figure Chubu Nonalcoholic Steatohepatitis (Nash) Consumption Share by Types in 2014

    • Figure Chubu Nonalcoholic Steatohepatitis (Nash) Consumption Share by Types in 2018

    • Figure Chubu Nonalcoholic Steatohepatitis (Nash) Consumption Share by Types in 2026

    • Table Chubu Nonalcoholic Steatohepatitis (Nash) Consumption by End-Users from 2014 to 2026

    • Table Chubu Nonalcoholic Steatohepatitis (Nash) Consumption Share by End-Users from 2014 to 2026

    • Figure Chubu Nonalcoholic Steatohepatitis (Nash) Consumption Share by End-Users in 2014

    • Figure Chubu Nonalcoholic Steatohepatitis (Nash) Consumption Share by End-Users in 2018

    • Figure Chubu Nonalcoholic Steatohepatitis (Nash) Consumption Share by End-Users in 2026

    • Table Kinki Nonalcoholic Steatohepatitis (Nash) Consumption by Types from 2014 to 2026

    • Table Kinki Nonalcoholic Steatohepatitis (Nash) Consumption Share by Types from 2014 to 2026

    • Figure Kinki Nonalcoholic Steatohepatitis (Nash) Consumption Share by Types in 2014

    • Figure Kinki Nonalcoholic Steatohepatitis (Nash) Consumption Share by Types in 2018

    • Figure Kinki Nonalcoholic Steatohepatitis (Nash) Consumption Share by Types in 2026

    • Table Kinki Nonalcoholic Steatohepatitis (Nash) Consumption by End-Users from 2014 to 2026

    • Table Kinki Nonalcoholic Steatohepatitis (Nash) Consumption Share by End-Users from 2014 to 2026

    • Figure Kinki Nonalcoholic Steatohepatitis (Nash) Consumption Share by End-Users in 2014

    • Figure Kinki Nonalcoholic Steatohepatitis (Nash) Consumption Share by End-Users in 2018

    • Figure Kinki Nonalcoholic Steatohepatitis (Nash) Consumption Share by End-Users in 2026

    • Table Chugoku Nonalcoholic Steatohepatitis (Nash) Consumption by Types from 2014 to 2026

    • Table Chugoku Nonalcoholic Steatohepatitis (Nash) Consumption Share by Types from 2014 to 2026

    • Figure Chugoku Nonalcoholic Steatohepatitis (Nash) Consumption Share by Types in 2014

    • Figure Chugoku Nonalcoholic Steatohepatitis (Nash) Consumption Share by Types in 2018

    • Figure Chugoku Nonalcoholic Steatohepatitis (Nash) Consumption Share by Types in 2026

    • Table Chugoku Nonalcoholic Steatohepatitis (Nash) Consumption by End-Users from 2014 to 2026

    • Table Chugoku Nonalcoholic Steatohepatitis (Nash) Consumption Share by End-Users from 2014 to 2026

    • Figure Chugoku Nonalcoholic Steatohepatitis (Nash) Consumption Share by End-Users in 2014

    • Figure Chugoku Nonalcoholic Steatohepatitis (Nash) Consumption Share by End-Users in 2018

    • Figure Chugoku Nonalcoholic Steatohepatitis (Nash) Consumption Share by End-Users in 2026

    • Table Shikoku Nonalcoholic Steatohepatitis (Nash) Consumption by Types from 2014 to 2026

    • Table Shikoku Nonalcoholic Steatohepatitis (Nash) Consumption Share by Types from 2014 to 2026

    • Figure Shikoku Nonalcoholic Steatohepatitis (Nash) Consumption Share by Types in 2014

    • Figure Shikoku Nonalcoholic Steatohepatitis (Nash) Consumption Share by Types in 2018

    • Figure Shikoku Nonalcoholic Steatohepatitis (Nash) Consumption Share by Types in 2026

    • Table Shikoku Nonalcoholic Steatohepatitis (Nash) Consumption by End-Users from 2014 to 2026

    • Table Shikoku Nonalcoholic Steatohepatitis (Nash) Consumption Share by End-Users from 2014 to 2026

    • Figure Shikoku Nonalcoholic Steatohepatitis (Nash) Consumption Share by End-Users in 2014

    • Figure Shikoku Nonalcoholic Steatohepatitis (Nash) Consumption Share by End-Users in 2018

    • Figure Shikoku Nonalcoholic Steatohepatitis (Nash) Consumption Share by End-Users in 2026

    • Table Kyushu Nonalcoholic Steatohepatitis (Nash) Consumption by Types from 2014 to 2026

    • Table Kyushu Nonalcoholic Steatohepatitis (Nash) Consumption Share by Types from 2014 to 2026

    • Figure Kyushu Nonalcoholic Steatohepatitis (Nash) Consumption Share by Types in 2014

    • Figure Kyushu Nonalcoholic Steatohepatitis (Nash) Consumption Share by Types in 2018

    • Figure Kyushu Nonalcoholic Steatohepatitis (Nash) Consumption Share by Types in 2026

    • Table Kyushu Nonalcoholic Steatohepatitis (Nash) Consumption by End-Users from 2014 to 2026

    • Table Kyushu Nonalcoholic Steatohepatitis (Nash) Consumption Share by End-Users from 2014 to 2026

    • Figure Kyushu Nonalcoholic Steatohepatitis (Nash) Consumption Share by End-Users in 2014

    • Figure Kyushu Nonalcoholic Steatohepatitis (Nash) Consumption Share by End-Users in 2018

    • Figure Kyushu Nonalcoholic Steatohepatitis (Nash) Consumption Share by End-Users in 2026

    • Table Company Profile and Development Status of Astazeneca Plc

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Astazeneca Plc

    • Figure Sales and Growth Rate Analysis of Astazeneca Plc

    • Figure Revenue and Market Share Analysis of Astazeneca Plc

    • Table Product and Service Introduction of Astazeneca Plc

    • Table Company Profile and Development Status of Enzo Biochem, Inc

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Enzo Biochem, Inc

    • Figure Sales and Growth Rate Analysis of Enzo Biochem, Inc

    • Figure Revenue and Market Share Analysis of Enzo Biochem, Inc

    • Table Product and Service Introduction of Enzo Biochem, Inc

    • Table Company Profile and Development Status of Novo Nordisk

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Novo Nordisk

    • Figure Sales and Growth Rate Analysis of Novo Nordisk

    • Figure Revenue and Market Share Analysis of Novo Nordisk

    • Table Product and Service Introduction of Novo Nordisk

    • Table Company Profile and Development Status of Gilead Science

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Gilead Science

    • Figure Sales and Growth Rate Analysis of Gilead Science

    • Figure Revenue and Market Share Analysis of Gilead Science

    • Table Product and Service Introduction of Gilead Science

    • Table Company Profile and Development Status of Boehringer Ingelheim

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Boehringer Ingelheim

    • Figure Sales and Growth Rate Analysis of Boehringer Ingelheim

    • Figure Revenue and Market Share Analysis of Boehringer Ingelheim

    • Table Product and Service Introduction of Boehringer Ingelheim

    • Table Company Profile and Development Status of Nimbus Therapeutics

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Nimbus Therapeutics

    • Figure Sales and Growth Rate Analysis of Nimbus Therapeutics

    • Figure Revenue and Market Share Analysis of Nimbus Therapeutics

    • Table Product and Service Introduction of Nimbus Therapeutics

    • Table Company Profile and Development Status of Verva Pharmaceuticals

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Verva Pharmaceuticals

    • Figure Sales and Growth Rate Analysis of Verva Pharmaceuticals

    • Figure Revenue and Market Share Analysis of Verva Pharmaceuticals

    • Table Product and Service Introduction of Verva Pharmaceuticals

    • Table Company Profile and Development Status of Galmed Pharmaceuticals Ltd.

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Galmed Pharmaceuticals Ltd.

    • Figure Sales and Growth Rate Analysis of Galmed Pharmaceuticals Ltd.

    • Figure Revenue and Market Share Analysis of Galmed Pharmaceuticals Ltd.

    • Table Product and Service Introduction of Galmed Pharmaceuticals Ltd.

    • Table Company Profile and Development Status of Islet Sciences

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Islet Sciences

    • Figure Sales and Growth Rate Analysis of Islet Sciences

    • Figure Revenue and Market Share Analysis of Islet Sciences

    • Table Product and Service Introduction of Islet Sciences

    • Table Company Profile and Development Status of AstraZeneca

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of AstraZeneca

    • Figure Sales and Growth Rate Analysis of AstraZeneca

    • Figure Revenue and Market Share Analysis of AstraZeneca

    • Table Product and Service Introduction of AstraZeneca

    • Table Company Profile and Development Status of GENFIT SA

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of GENFIT SA

    • Figure Sales and Growth Rate Analysis of GENFIT SA

    • Figure Revenue and Market Share Analysis of GENFIT SA

    • Table Product and Service Introduction of GENFIT SA

    • Table Company Profile and Development Status of Connexios Life Sciences

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Connexios Life Sciences

    • Figure Sales and Growth Rate Analysis of Connexios Life Sciences

    • Figure Revenue and Market Share Analysis of Connexios Life Sciences

    • Table Product and Service Introduction of Connexios Life Sciences

    • Table Company Profile and Development Status of Tobira Therapeutics, Inc.

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Tobira Therapeutics, Inc.

    • Figure Sales and Growth Rate Analysis of Tobira Therapeutics, Inc.

    • Figure Revenue and Market Share Analysis of Tobira Therapeutics, Inc.

    • Table Product and Service Introduction of Tobira Therapeutics, Inc.

    • Table Company Profile and Development Status of Cerenis Therapeutics

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Cerenis Therapeutics

    • Figure Sales and Growth Rate Analysis of Cerenis Therapeutics

    • Figure Revenue and Market Share Analysis of Cerenis Therapeutics

    • Table Product and Service Introduction of Cerenis Therapeutics

    • Table Company Profile and Development Status of Viking Therapeutics

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Viking Therapeutics

    • Figure Sales and Growth Rate Analysis of Viking Therapeutics

    • Figure Revenue and Market Share Analysis of Viking Therapeutics

    • Table Product and Service Introduction of Viking Therapeutics

    • Table Company Profile and Development Status of Immuron Ltd

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Immuron Ltd

    • Figure Sales and Growth Rate Analysis of Immuron Ltd

    • Figure Revenue and Market Share Analysis of Immuron Ltd

    • Table Product and Service Introduction of Immuron Ltd

    • Table Company Profile and Development Status of Intercepts Pharmaceuticals

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Intercepts Pharmaceuticals

    • Figure Sales and Growth Rate Analysis of Intercepts Pharmaceuticals

    • Figure Revenue and Market Share Analysis of Intercepts Pharmaceuticals

    • Table Product and Service Introduction of Intercepts Pharmaceuticals

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US